Press Release

November 10, 2021
1 min read

FDA grants fast track designation to bemcentinib for advanced NSCLC


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA granted fast track designation to bemcentinib for treatment of certain patients with non-small cell lung cancer.

The designation applies to use of the agent in combination with an anti-PD-1 therapy for individuals with STK11-altered advanced or metastatic NSCLC who have no actionable mutations.

Doctor analyzing lung x-ray
Source: Adobe Stock.

Bemcentinib (BerGenBio) is a selective AXL inhibitor.

Preclinical research of the agent in NSCLC mouse models harboring STK11 mutations showed bemcentinib led to expansion of tumor-associated T cells and restored therapeutic response to anti-PD-1 checkpoint inhibition, according to a BerGenBio-issued press release.

Data from a phase 2 study in advanced NSCLC showed all three evaluable patients with identified STK11/LKB1 mutations achieved objective clinical response or clinical benefit to the combination of bemcentinib and pembrolizumab (Keytruda, Merck), an anti-PD-1 antibody.

An estimated 20% of patients with NSCLC harbor STK11 mutations, according to the release.

“[This represents] a large, identifiable subgroup of patients who may benefit from treatment with an AXL inhibitor such as bemcentinib,” Martin Olin, CEO of BerGenBio, said in the release.